The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review
Open accessAbstract
Over the past decade, artificial intelligence (AI) and machine learning (ML) have become the breakthrough technology most anticipated to have a transformative effect on pharmaceutical research and development (R&D). This is partially driven by revolutionary advances in computational technology and the parallel dissipation of previous constraints to the collection/processing of large volumes of data. Meanwhile, the cost of bringing new drugs to market and to patients has become prohibitively expensive. Recognizing these headwinds, AI/ML techniques are appealing to the pharmaceutical industry due to their automated nature, predictive capabilities, and the consequent expected increase in efficiency. ML approaches have been used in drug discovery over the past 15–20 years with increasing sophistication. The most recent aspect of drug development where positive disruption from AI/ML is starting to occur, is in clinical trial design, conduct, and analysis. The COVID-19 pandemic may further accelerate utilization of AI/ML in clinical trials due to an increased reliance on digital technology in clinical trial conduct. As we move towards a world where there is a growing integration of AI/ML into R&D, it is critical to get past the related buzz-words and noise. It is equally important to recognize that the scientific method is not obsolete when making inferences about data. Doing so will help in separating hope from hype and lead to informed decision-making on the optimal use of AI/ML in drug development. This manuscript aims to demystify key concepts, present use-cases and finally offer insights and a balanced view on the optimal use of AI/ML methods in R&D. Graphical abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved protein structure prediction using potentials from deep learning
Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A., Nelson, A. W. R., Bridgland, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1923-7 · Cited by 3,378
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 1×
“…is a long and expensive process with a low success rate as evidenced by the following esti - mates: average R&D investment is $1.3 billion per drug [1 ]; median development time for each drug ranges from 5.9 to 7.2 years for non-oncology and 13.1 years for oncol - ogy; and proportion of all…”
BackgroundInfluentialThe Protein-Folding Problem, 50 Years On
Dill, K. A., & MacCallum, J. L. (2012) · Science · doi:10.1126/science.1219021 · Cited by 1,699
Estimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Woodcock, J., & LaVange, L. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510062 · Cited by 1,020
Beck, B. R., Shin, B., Choi, Y., Park, S., & Kang, K. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.025 · Cited by 816
Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
Hwang, T. J., Carpenter, D., Lauffenburger, J. C., Wang, B., Franklin, J. M., & Kesselheim, A. S. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6008 · Cited by 442
Key cost drivers of pharmaceutical clinical trials in the United States
Sertkaya, A., Wong, H.-H., Jessup, A., & Beleche, T. (2016) · Clinical Trials · doi:10.1177/1740774515625964 · Cited by 401
Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A., Nelson, A. W. R., Bridgland, A., et al. (2019) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.25834 · Cited by 347
Efficiencies of platform clinical trials: A vision of the future
Saville, B. R., & Berry, S. M. (2016) · Clinical Trials · doi:10.1177/1740774515626362 · Cited by 315
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Artificial Intelligence in Pharmaceutical and Healthcare Research
Bhattamisra, S. K., Banerjee, P., Gupta, P., Mayuren, J., Patra, S., & Candasamy, M. (2023) · Big Data and Cognitive Computing · doi:10.3390/bdcc7010010 · Cited by 257
Singh, S., Kumar, R., Payra, S., & Singh, S. K. (2023) · Cureus · doi:10.7759/cureus.44359 · Cited by 154
Machine Learning and Artificial Intelligence in the Multi-Omics Approach to Gut Microbiota
Rozera, T., Pasolli, E., Segata, N., & Ianiro, G. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.02.035 · Cited by 112
Lu, X., Yang, C., Liang, L., Hu, G., Zhong, Z., & Jiang, Z. (2024) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocae243 · Cited by 77
Metadata
- Authors
- Kolluri, S., Lin, J., Liu, R., Zhang, Y., & Zhang, W.
- Venue
- The AAPS Journal
- Published
- 2022-01-04
- Volume
- 24
- Issue
- 1
- Pages
- 19-19
- ISSN
- 1550-7416 (ISSN-L)
- OpenAlex
- W4205739101
- Cited by
- 286
- References
- 16
- FWCI
- 29.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review. https://app.cochat.ai/papers/10.1208/s12248-021-00644-3
- The paper
- Kolluri, S., Lin, J., Liu, R., Zhang, Y., & Zhang, W. (2022). Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review. The AAPS Journal. https://doi.org/10.1208/s12248-021-00644-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.